Skip to main content
Colorado General AssemblyToggle Main Menu
Agency NameToggle Agency Menu

i_opioidsubstance_2017a_2017-07-10t09:09:20z7 Hearing Summary

Date: 07/10/2017

Location: RM 271


Public Comment


Votes: View--> Action Taken:
<none> <none>

04:16 PM -- Public Comment

Representative Pettersen opened the meeting for public testimony.

04:17 PM --
Jessica LeRoux, representing herself, testified regarding the dangers of benzodiazepine withdrawal. Discussion with the committee ensued.

04:20 PM --
Cindy Sovine-Miller, representing herself, distributed two handouts to the committee (Attachments P and Q) and testified regarding the safety of medical marijuana compared to other pain medications. Ms. Sovine-Miller responded to questions from the committee.

17Opioid0710AttachP.pdf17Opioid0710AttachP.pdf 17Opioid0710AttachQ.pdf17Opioid0710AttachQ.pdf

Senator Aguilar commented on ideas for legislation, including limiting prescriptions for new patients, renewing the Attorney General's Task Force, integrating the PDMP into electronic health records, tracking additional drugs in the PDMP, removing pain as a patient 'vital sign', adjusting prescription formulations, and controlling the cost of generic prescriptions.

04:31 PM --
Dale Terasaki, representing himself, testified regarding the effectiveness of safe injection sites to prevent overdoses.

04:32 PM --
Denise Vincioni, representing the Denver Recovery Group, testified regarding the substance use disorder recovery workforce shortage.

04:34 PM

Representative Pettersen reminded the committee that the next meeting is scheduled for August 1, 2017, and requested feedback on the draft agenda for the next meeting.

04:36 PM

Representative Pettersen adjourned the meeting.

Colorado legislature email addresses ending in are no longer active. Please replace with for Colorado legislature email addresses. Details

The effective date for bills enacted without a safety clause is August 7, 2024, if the General Assembly adjourns sine die on May 8, 2024, unless otherwise specified. Details